The open access movement has shaken up the publishing landscape. In traditional publishing, research literature could only be accessed through a subscription or individual payments. Open access literature, in contrast, is freely available online for the general public, and often has few or no copyright restrictions on its use and reuse. This affords many benefits: research is available to more readers, authors get to retain certain rights, and research can be disseminated and built upon much faster. Over 90,000 articles were published for immediate open access in 2020 (Open Access 2020 Initiative [OA2020], 2020). What else has been happening with open access? Here are a couple of updates.
More than 130 transformative agreements, compliant with ESAC guidelines, have been signed to date, representing 19 countries and 32 publishers. These are intended to help organizations transition from a subscription model to open access publishing. cOAlition S, a consortium of funders including the Wellcome Trust, the World Health Organization, and the Bill and Melinda Gates Foundation, has put out a statement saying that, after January 1, 2021, it will no longer financially support agreements that do not adhere to these guidelines (OA2020, 2020).
Preprints (the version of an article that is pre-peer review and -acceptance to a journal) have also made the news this year because of the COVID-19 pandemic. With so much unknown about the virus, research couldn’t get published fast enough, and many have been utilizing preprints to get information on it. Servers like medRxiv and MedRN contain a wealth of information on COVID-19 and other conditions. The National Library of Medicine also announced their NIH Preprint Pilot in June, pulling in preprints from preprint servers so that they can be searched in PubMed.
Now more than ever, having freely available research is vital, and open access helps make this possible.
References:
Open Access 2020 Initiative. (2020). OA2020 progress report. Retrieved from https://oa2020.org/progress-report/
- To learn more about open access, visit the library's scholarly communications guide at: libguides.mssm.edu/scholcomm.
- To learn more about preprints, check out the library's class on Introduction to Preprints, via our YouTube Channel.
Each month Levy Library showcases the achievements of Mount Sinai faculty and researchers by highlighting an article and its altmetrics. Altmetrics are alternative measures of impact that capture non-traditional data like abstract views, article downloads, and social media activity. Our altmetrics data is provided by the PlumX platform.
This month we highlight a publication from a member of our Library team, Rachel Pinotti. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes:
SUMMARY
The description of a so-called cytokine storm in patients with COVID-19 has prompted consideration of anti-cytokine therapies, particularly interleukin-6 antagonists. However, direct systematic comparisons of COVID-19 with other critical illnesses associated with elevated cytokine concentrations have not been reported. In this Rapid Review, we report the results of a systematic review and meta-analysis of COVID-19 studies published or posted as preprints between Nov 1, 2019, and April 14, 2020, in which interleukin-6 concentrations in patients with severe or critical disease were recorded. 25 COVID-19 studies (n=1245 patients) were ultimately included. Comparator groups included four trials each in sepsis (n=5320), cytokine release syndrome (n=72), and acute respiratory distress syndrome unrelated to COVID-19 (n=2767). In patients with severe or critical COVID-19, the pooled mean serum interleukin-6 concentration was 36·7 pg/mL (95% CI 21·6–62·3 pg/mL; I2=57·7%). Mean interleukin-6 concentrations were nearly 100 times higher in patients with cytokine release syndrome (3110·5 pg/mL, 632·3–15 302·9 pg/mL; p<0·0001), 27 times higher in patients with sepsis (983·6 pg/mL, 550·1–1758·4 pg/mL; p<0·0001), and 12 times higher in patients with acute respiratory distress syndrome unrelated to COVID-19 (460 pg/mL, 216·3–978·7 pg/mL; p<0·0001). Our findings question the role of a cytokine storm in COVID-19-induced organ dysfunction. Many questions remain about the immune features of COVID-19 and the potential role of anti-cytokine and immune-modulating treatments in patients with the disease.
KEY MESSAGES
Alternative models of organ dysfunction in COVID-19, such as endovasculitis, direct viral injury and lymphodepletion, or viral-induced immunosuppression, might be worth considering
View the PlumX profile to learn more about the metrics details of this publication.
Read this publication in The Lancet Respiratory Medicine